130 related articles for article (PubMed ID: 2056772)
1. Plasminogen activator inhibitor-2 in patients with monocytic leukemia.
Scherrer A; Kruithof EK; Grob JP
Leukemia; 1991 Jun; 5(6):479-86. PubMed ID: 2056772
[TBL] [Abstract][Full Text] [Related]
2. Flow cytometry immunophenotypic characteristics of monocytic population in acute monocytic leukemia (AML-M5), acute myelomonocytic leukemia (AML-M4), and chronic myelomonocytic leukemia (CMML).
Gorczyca W
Methods Cell Biol; 2004; 75():665-77. PubMed ID: 15603447
[No Abstract] [Full Text] [Related]
3. [Factors related to prognosis and relapse in acute myelomonocytic and monocytic leukemias (M4 and M5)].
Koyama A; Shirakawa C; Masaki H; Horiuchi F; Hamazaki H; Fujimoto T; Irimajiri K; Horiuchi A
Rinsho Ketsueki; 1990 Nov; 31(11):1787-93. PubMed ID: 2287062
[TBL] [Abstract][Full Text] [Related]
4. Assessment of monocytic component in acute myelomonocytic and monocytic/monoblastic leukemias by a chemiluminescent assay.
da Fonseca LM; Brunetti IL; Campa A; Catalani LH; Calado RT; Falcão RP
Hematol J; 2003; 4(1):26-30. PubMed ID: 12692517
[TBL] [Abstract][Full Text] [Related]
5. Expression of CD56/NCAM on hematopoietic malignant cells. A useful marker for acute monocytic and megakaryocytic leukemias.
Ikushima S; Yoshihara T; Matsumura T; Misawa S; Morioka Y; Hibi S; Imashuku S
Int J Hematol; 1991 Oct; 54(5):395-403. PubMed ID: 1721853
[TBL] [Abstract][Full Text] [Related]
6. [Plasma concentrations of plasminogen activator inhibitor 2 in patients with hematological malignancies and their clinical significance].
Shimmyozu K; Machigashira N; Itoyama T; Tara M; Maruyama I; Osame M
Rinsho Ketsueki; 1991 Feb; 32(2):173-5. PubMed ID: 2027244
[TBL] [Abstract][Full Text] [Related]
7. [The significance of plasminogen activator inhibitor 2 in patients with hematologic malignancies].
Cetkovský P; Koza V; Cepelák V; Vít L
Vnitr Lek; 1993 Sep; 39(9):871-5. PubMed ID: 8212641
[TBL] [Abstract][Full Text] [Related]
8. The THP-1 cell line is a urokinase-secreting mononuclear phagocyte with a novel defect in the production of plasminogen activator inhibitor-2.
Gross TJ; Sitrin RG
J Immunol; 1990 Mar; 144(5):1873-9. PubMed ID: 2307845
[TBL] [Abstract][Full Text] [Related]
9. Immunophenotypic, cytogenetic and molecular investigations in two cases of CALLA positive acute myeloid leukemia.
Fagioli F; Lanza F; Carli MG; Cuneo A; Gandini D; Del Senno L; Castoldi G
Haematologica; 1990; 75(5):407-11. PubMed ID: 2097259
[TBL] [Abstract][Full Text] [Related]
10. Plasminogen activators and their inhibitors in leukemic cell homogenates.
Wada H; Kumeda Y; Ogasawara Z; Ohiwa M; Kaneko T; Tamaki S; Ohno T; Kageyama S; Kobayashi T; Deguchi K
Am J Hematol; 1993 Feb; 42(2):166-70. PubMed ID: 8438877
[TBL] [Abstract][Full Text] [Related]
11. The value of immunohistochemistry for CD14, CD123, CD33, myeloperoxidase and CD68R in the diagnosis of acute and chronic myelomonocytic leukaemias.
Rollins-Raval MA; Roth CG
Histopathology; 2012 May; 60(6):933-42. PubMed ID: 22348485
[TBL] [Abstract][Full Text] [Related]
12. Skin involvement in myelogenous leukemia: morphologic and immunophenotypic heterogeneity of skin infiltrates.
Kaiserling E; Horny HP; Geerts ML; Schmid U
Mod Pathol; 1994 Sep; 7(7):771-9. PubMed ID: 7824512
[TBL] [Abstract][Full Text] [Related]
13. [Effect of cyclic AMP and phorbol ester on PAI-2 synthesis in a leukemic cell line PL-21 and on u-PA secretion in a pre-B cell lymphoma cell line RC-K8].
Niiya K; Sakuragawa N
Nihon Rinsho; 1992 Feb; 50(2):325-9. PubMed ID: 1319513
[TBL] [Abstract][Full Text] [Related]
14. High expression of urokinase plasminogen activator receptor (UPA-R) in acute myeloid leukemia (AML) is associated with worse prognosis.
Graf M; Reif S; Hecht K; Pelka-Fleischer R; Pfister K; Schmetzer H
Am J Hematol; 2005 May; 79(1):26-35. PubMed ID: 15849776
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of proteolytic activity in 12-O-tetradecanoyl-phorbol-13-acetate-induced K562 leukemia cell cultures: depletion of active urokinase by excess type 1 plasminogen activator inhibitor.
Alitalo R; Andersson LC; Tapiovaara H; Sistonen L; Vaheri A; Stephens R
J Cell Physiol; 1989 Jul; 140(1):119-30. PubMed ID: 2500450
[TBL] [Abstract][Full Text] [Related]
16. Severe cardiopulmonary complications consistent with systemic inflammatory response syndrome caused by leukemia cell lysis in childhood acute myelomonocytic or monocytic leukemia.
Hijiya N; Metzger ML; Pounds S; Schmidt JE; Razzouk BI; Rubnitz JE; Howard SC; Nunez CA; Pui CH; Ribeiro RC
Pediatr Blood Cancer; 2005 Jan; 44(1):63-9. PubMed ID: 15368547
[TBL] [Abstract][Full Text] [Related]
17. [Childhood acute myeloblastic leukemias. Report of 21 cases].
Laatiri MA; Chehata S; Amouri A; Bouaouina N; Chatti S; Saad A; Ennabli S
Tunis Med; 2000 Mar; 78(3):167-71. PubMed ID: 11026819
[TBL] [Abstract][Full Text] [Related]
18. Expression of the interleukin 6 gene in acute myeloid leukemia and myelodysplastic syndromes: a report on 49 cases.
Collyn d'Hooghe M; Fenaux P; Lantoine D; Loucheux-Lefebvre M; Kerckaert JP
Nouv Rev Fr Hematol (1978); 1990; 32(3):175-7. PubMed ID: 2216700
[TBL] [Abstract][Full Text] [Related]
19. [Ferritin in acute leukemia. Serum ferritin concentration as a nonspecific tumor marker for M1 and M2 myeloid leukemia].
Aulbert E; Fromm H; Hornemann H
Med Klin (Munich); 1991 Jun; 86(6):297-304. PubMed ID: 1886510
[TBL] [Abstract][Full Text] [Related]
20. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
